Central Giant Cell Granuloma Treated with Intralesional Corticosteroid Injections and Bisphosphonates: A Long-Term Follow-Up Case Study

  • Raíssa Pinheiro de Mendonça
  • Geovanni Pereira Mitre
  • Flavio Henrique Real
  • Maria Sueli da Silva Kataoka
  • Sérgio de Melo Alves Júnior
  • Paulo Vianna
  • Newton Guerreiro Da Silva Júnior
  • João de Jesus Viana PinheiroEmail author
Sine qua non Clinicopathologic Correlation


Central giant cell granuloma (CGCG) is a benign intraosseous lesion of the head and neck with potential for aggressive and locally destructive behaviour. Lesions of the maxilla tend to expand more than those of the mandible due to the thinner cortices and spongy tissue of this location. Surgical removal is the most common treatment; however, it may be disfiguring in aggressive cases, especially for lesions located in the maxilla. Alternative treatments, such as intralesional corticosteroid injections, have been performed with satisfactory results. We report a case of a 12-year-old female patient with a CGCG of the left maxilla that was treated with 40 doses of intralesional triamcinolone acetonide infiltrations combined with alendronate sodium and calcium carbonate. Clinical and imaging follow-up over 12 years demonstrates improvement in the patient’s condition.


Corticosteroid Granuloma Giant cell Injections Intralesional Triamcinolone acetonide 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. World Health Organization classification of head and neck tumours. Lyon: IARC Press; 2017. p. 256.Google Scholar
  2. 2.
    Garg P, Jain J, De N, Chatterjee K. A central giant cell granuloma in posterior part of maxilla: a case report. Int J Surg Case Rep. 2017;30:222–5.CrossRefGoogle Scholar
  3. 3.
    Jerkins D, Malotky M, Miremadi R, Dole M. Central giant cell granuloma of the mandible requiring multiple treatment modalities: a case report. J Oral Maxillofac Surg. 2016;74(8):1596–607.CrossRefGoogle Scholar
  4. 4.
    Rawashdeh MA, Bataineh AB, Al-Khateeb T. Long-term clinical and radiological outcomes of surgical management of central giant cell granuloma of the maxilla. Int J Oral Maxillofac Surg. 2006;35(1):60–6.CrossRefGoogle Scholar
  5. 5.
    de Lange J, van den Akker HP. Clinical and radiological features of central giant-cell lesions of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:464–70.CrossRefGoogle Scholar
  6. 6.
    Osterne RL, Araújo PM, de Souza-Carvalho AC, Cavalcante RB, Sant’Ana E, Nongueira RL. Intralesional corticosteroid injections in the treatment of central giant cell lesions of the jaws: a meta-analytic study. Med Oral Patol Oral Cir Bucal. 2013;18(2):e226–32.CrossRefGoogle Scholar
  7. 7.
    Dolanmaz D, Esen A, Mihmanlı A, Işık K. Management of central giant cell granuloma of the jaws with intralesional steroid injection and review of the literature. Oral Maxillofac Surg. 2016;20(2):203–9.CrossRefGoogle Scholar
  8. 8.
    de Oliveira JP, Olivete F, de Oliveira ND, et al. Combination therapies for the treatment of recurrent central giant cell lesion in the maxilla: a case report. J Med Case Rep. 2017;11(1):74.CrossRefGoogle Scholar
  9. 9.
    Wendt FP, Torriani MA, Gomes AP, de Araujo LM, Torriani DD. Intralesional corticosteroid injection for central giant cell granuloma: an alternative treatment for children. J Dent Child. 2009;76(3):229–32.Google Scholar
  10. 10.
    da Rosa MRP, de Sá JL, Martins VB, de Oliveira MV. Central giant cells lesion: report of a conservative management. Eur J Dent. 2018;12(2):305–10.CrossRefGoogle Scholar
  11. 11.
    Schreuder WH, van den Berg H, Westermann AM, Peacock ZS, de Lange J. Pharmacological and surgical therapy for the central giant cell granuloma: a long-term retrospective cohort study. J Craniomaxillofac Surg. 2017;45(2):232–43.CrossRefGoogle Scholar
  12. 12.
    Naidu A, Malmquist MP, Denham CA, Schow SR. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014;72(12):2469–84.CrossRefGoogle Scholar
  13. 13.
    Vered M, Buchner A, Dayan D. Immunohistochemical expression of glucocorticoid and calcitonin receptors as a tool for selecting therapeutic approach in central giant cell granuloma of the jawbones. Int J Oral Maxillofac Surg. 2006;35(8):756–60.CrossRefGoogle Scholar
  14. 14.
    Ananchenko G, Novakovic J, Tikhomirova A. Alendronate sodium. Profiles Drug Subst Excip Relat Methodol. 2013;38:1–33.CrossRefGoogle Scholar
  15. 15.
    Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18(5):919–24.CrossRefGoogle Scholar
  16. 16.
    Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95(5A):48S–52S.CrossRefGoogle Scholar
  17. 17.
    da Silva NG, Carreira AS, Pedreira EN, Tuji FM, Ortega KL, de Jesus Viana Pinheiro J. Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections. Head Face Med. 2012;8:23.CrossRefGoogle Scholar
  18. 18.
    Kurtz M, Mesa M, Alberto P. Treatment of a central giant cell lesion of the mandible with intralesional glucocorticosteroids. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:636–7.CrossRefGoogle Scholar
  19. 19.
    Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.CrossRefGoogle Scholar
  20. 20.
    Sarinho ESC, Melo VMPP. Glucocorticoid-induced bone disease: mechanisms and importance in pediatric practice. Rev Paul Pediatr. 2017;35(2):207–15.CrossRefGoogle Scholar
  21. 21.
    Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology. 2005;44(6):813–8.CrossRefGoogle Scholar
  22. 22.
    Hernandez M, Phulpin B, Mansuy L, Droz D. Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review. J Oral Pathol Med. 2017;46(5):321–6.CrossRefGoogle Scholar
  23. 23.
    Nogueira RL, Teixeira RC, Cavalcante RB, Ribeiro RA, Rabenhosrt SH. Intralesional injection of triamcinolone hexacetonide as an alternative treatment for central giant-cell granuloma in 21 cases. Int J Oral Maxillofac Surg. 2010;39(12):1204–10.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Raíssa Pinheiro de Mendonça
    • 1
  • Geovanni Pereira Mitre
    • 2
  • Flavio Henrique Real
    • 3
  • Maria Sueli da Silva Kataoka
    • 2
  • Sérgio de Melo Alves Júnior
    • 2
  • Paulo Vianna
    • 4
  • Newton Guerreiro Da Silva Júnior
    • 3
  • João de Jesus Viana Pinheiro
    • 2
    • 5
    Email author
  1. 1.Department of Oral Pathology, School of DentistryFederal University of CearaFortalezaBrazil
  2. 2.Department of Oral Pathology, School of DentistryFederal University of ParaBelemBrazil
  3. 3.Department of Oral and Maxillofacial Surgery, School of DentistryFederal University of Para, Avenida Augusto CorreaBelemBrazil
  4. 4.BelemBrazil
  5. 5.Cell Culture Laboratory, Department of Oral Pathology, School of DentistryFederal University of Para - UFPA - Institute of Health SciencesBelemBrazil

Personalised recommendations